104 related articles for article (PubMed ID: 25474526)
1. Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors.
Cervi G; Magnaghi P; Asa D; Avanzi N; Badari A; Borghi D; Caruso M; Cirla A; Cozzi L; Felder E; Galvani A; Gasparri F; Lomolino A; Magnuson S; Malgesini B; Motto I; Pasi M; Rizzi S; Salom B; Sorrentino G; Troiani S; Valsasina B; O'Brien T; Isacchi A; Donati D; D'Alessio R
J Med Chem; 2014 Dec; 57(24):10443-54. PubMed ID: 25474526
[TBL] [Abstract][Full Text] [Related]
2. Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships.
Polucci P; Magnaghi P; Angiolini M; Asa D; Avanzi N; Badari A; Bertrand J; Casale E; Cauteruccio S; Cirla A; Cozzi L; Galvani A; Jackson PK; Liu Y; Magnuson S; Malgesini B; Nuvoloni S; Orrenius C; Sirtori FR; Riceputi L; Rizzi S; Trucchi B; O'Brien T; Isacchi A; Donati D; D'Alessio R
J Med Chem; 2013 Jan; 56(2):437-50. PubMed ID: 23245311
[TBL] [Abstract][Full Text] [Related]
3. 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97).
Bursavich MG; Parker DP; Willardsen JA; Gao ZH; Davis T; Ostanin K; Robinson R; Peterson A; Cimbora DM; Zhu JF; Richards B
Bioorg Med Chem Lett; 2010 Mar; 20(5):1677-9. PubMed ID: 20137940
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.
Wang X; Bai E; Zhou H; Sha S; Miao H; Qin Y; Liu Z; Wang J; Zhang H; Lei M; Liu J; Hai O; Zhu Y
Bioorg Med Chem; 2019 Feb; 27(3):533-544. PubMed ID: 30606672
[TBL] [Abstract][Full Text] [Related]
5. A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
Zhang G; Li S; Wang F; Jones AC; Goldberg AFG; Lin B; Virgil S; Stoltz BM; Deshaies RJ; Chou TF
Eur J Med Chem; 2021 Mar; 213():113148. PubMed ID: 33476933
[TBL] [Abstract][Full Text] [Related]
6. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy.
Wang F; Li S; Gan T; Stott GM; Flint A; Chou TF
ChemMedChem; 2020 Apr; 15(8):685-694. PubMed ID: 32162487
[TBL] [Abstract][Full Text] [Related]
7. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.
Magnaghi P; D'Alessio R; Valsasina B; Avanzi N; Rizzi S; Asa D; Gasparri F; Cozzi L; Cucchi U; Orrenius C; Polucci P; Ballinari D; Perrera C; Leone A; Cervi G; Casale E; Xiao Y; Wong C; Anderson DJ; Galvani A; Donati D; O'Brien T; Jackson PK; Isacchi A
Nat Chem Biol; 2013 Sep; 9(9):548-56. PubMed ID: 23892893
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors.
Zhang Y; Xie X; Wang X; Wen T; Zhao C; Liu H; Zhao B; Zhu Y
Bioorg Med Chem; 2021 May; 38():116114. PubMed ID: 33831696
[TBL] [Abstract][Full Text] [Related]
9. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
Bastola P; Neums L; Schoenen FJ; Chien J
Mol Oncol; 2016 Dec; 10(10):1559-1574. PubMed ID: 27729194
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the aggregation-prevention activity of p97/valosin-containing protein.
Song C; Wang Q; Li CC
Biochemistry; 2007 Dec; 46(51):14889-98. PubMed ID: 18044963
[TBL] [Abstract][Full Text] [Related]
11. Going through the motions: the ATPase cycle of p97.
Pye VE; Dreveny I; Briggs LC; Sands C; Beuron F; Zhang X; Freemont PS
J Struct Biol; 2006 Oct; 156(1):12-28. PubMed ID: 16621604
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer.
Wang X; Wen T; Miao H; Hu W; Lei M; Zhu Y
Bioorg Med Chem; 2022 Nov; 74():117050. PubMed ID: 36228523
[TBL] [Abstract][Full Text] [Related]
13. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
[TBL] [Abstract][Full Text] [Related]
14. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.
Lan B; Chai S; Wang P; Wang K
Curr Mol Med; 2017; 17(9):608-618. PubMed ID: 29521227
[TBL] [Abstract][Full Text] [Related]
15. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Weihl CC; Dalal S; Pestronk A; Hanson PI
Hum Mol Genet; 2006 Jan; 15(2):189-99. PubMed ID: 16321991
[TBL] [Abstract][Full Text] [Related]
16. Rescue of growth defects of yeast cdc48 mutants by pathogenic IBMPFD-VCPs.
Takata T; Kimura Y; Ohnuma Y; Kawawaki J; Kakiyama Y; Tanaka K; Kakizuka A
J Struct Biol; 2012 Aug; 179(2):93-103. PubMed ID: 22728077
[TBL] [Abstract][Full Text] [Related]
17. Dendrimer-Based Selective Proteostasis-Inhibition Strategy to Control NSCLC Growth and Progression.
Walworth K; Bodas M; Campbell RJ; Swanson D; Sharma A; Vij N
PLoS One; 2016; 11(7):e0158507. PubMed ID: 27434122
[TBL] [Abstract][Full Text] [Related]
18. Roles of Cdc48 in regulated protein degradation in yeast.
Buchberger A
Subcell Biochem; 2013; 66():195-222. PubMed ID: 23479442
[TBL] [Abstract][Full Text] [Related]
19. UBXD1 is a VCP-interacting protein that is involved in ER-associated degradation.
Nagahama M; Ohnishi M; Kawate Y; Matsui T; Miyake H; Yuasa K; Tani K; Tagaya M; Tsuji A
Biochem Biophys Res Commun; 2009 May; 382(2):303-8. PubMed ID: 19275885
[TBL] [Abstract][Full Text] [Related]
20. The common phospholipid-binding activity of the N-terminal domains of PEX1 and VCP/p97.
Shiozawa K; Goda N; Shimizu T; Mizuguchi K; Kondo N; Shimozawa N; Shirakawa M; Hiroaki H
FEBS J; 2006 Nov; 273(21):4959-71. PubMed ID: 17018057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
